Posted by Michael Wonder on 08 Oct 2019
Humira, Rituxan top list of U.S. costliest drug price increases
8 October 2019 - AbbVie Inc’s arthritis drug Humira and Roche's cancer drug Rituxan top the list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.
The price hikes were more than twice the rate of medical inflation and were unsupported by any new clinical evidence, the Institute for Clinical and Economic Review said in the analysis.
It is the first such annual report by the Boston-based research group, which conducts cost effectiveness assessments of drugs.
